Denileukin diftitox
| File:Denileukin diftitox.png | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| ATC code | |
| Pharmacokinetic data | |
| Elimination half-life | 70-80 min |
| Identifiers | |
| |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C2560H4042N678O799S17 |
| Molar mass | 57647.3 g/mol |
Overview
Denileukin diftitox, otherwise known as Ontak is an antineoplastic agent, an engineered protein combining Interleukin-2 and Diphtheria toxin. This can bind to Interleukin-2 receptors[1] and introduce the diphtheria toxin into cells that express those receptors, killing the cells. In some Leukemias and Lymphomas malignant cells express these receptors, so denileukin diftitox can target these.
A recent study at the University of Louisville found the drug caused many stage IV malignant melanoma tumors to regress and even stabilize, extending patient life expectancy from about eight months to, as of now, more than a year- which is significant given metastatic malignant melanoma's grave prognosis and poor treatment response.
There is some evidence tying it to vision loss.[2]
References
- ↑ Turturro F (2007). "Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders". Expert Rev Anticancer Ther. 7 (1): 11–7. doi:10.1586/14737140.7.1.11. PMID 17187516.
- ↑ Park M, Liu GT, Piltz-Seymour J; et al. (2007). "Vision loss following denileukin diftitox treatment: a case report of possible posterior ischemic optic neuropathy". Leuk. Lymphoma. 48 (4): 808–11. doi:10.1080/10428190701268783. PMID 17454642.
External links
- Pages with script errors
- CS1 maint: Explicit use of et al.
- CS1 maint: Multiple names: authors list
- Pages with broken file links
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Cancer treatments